Carvedilol as secondary prophylaxis for variceal bleeding in hepatosplenic schistosomiasis

Background: Upper variceal bleeding (UVB) is a possible complication of portal hypertension secondary to hepatosplenic schistosomiasis (HSS). Propranolol is a non-selective beta-blocker used as secondary prophylaxis for UVB, but no previous studies have addressed carvedilol effects in rebleeding prevention. Methods: A retrospective exploratory study of 57 patients with chronic HSS and index UVB treated with endoscopic variceal Ligation and propranolol or carvedilol was conducted. The primary outcome was UVB-free time in the first 12 mo after the initial bleeding episode. Results: Propranolol was used for secondary UVB prophylaxis in 43 (75.4%) participants (median dose 80 [interquartile range - IQR 60-80] mg/d) and carvedilol in 14 (24.6%) participants (median dose 12.5 [IQR 7.9-25.0] mg/d). During a 12-mo follow-up, rebleeding was observed in 13 (22.8%) patients, 9 (20.9%) of those treated with propranolol and 4 (28.6%) treated with carvedilol (p=0.715). Mean time from the beginning of drug prophylaxis to rebleeding was 6 +/- 3 mo and there was no difference between that for propranolol vs carvedilol subgroups. Portal vein thrombosis did not influence the bleeding recurrence in either subgroup. Conclusion: Carvedilol may be equally effective as propranolol in preventing secondary UVB in HSS at 12-mo follow-up.

Automated summary

This study compared the effects of propranolol and carvedilol in preventing secondary UVB in HSS, and found that carvedilol may be equally effective as propranolol during a 12-month follow-up.